Tuberculosis is one of the most deadly infectious diseases that still causes significant burden of disease, particularly in the developing world. The emergence of resistance to first line agents severely limits the therapeutic options and threaten the ability to control dissemination of this disease. Fortunately, new drugs and regimens are now emerging as important alternatives against these organisms. Today, we disucss this topic with outstanding experts in the field.
- The burden of multidrug-resistant TB.
- New drugs and regimens for MDR TB.
- The current and future pipeline for TB
- Kelly Dooley, MD Ph.D. Professor and Addison B. Scoville, Jr., Chair in Medicine, Director, Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center. Past Editor of AAC
- Sean Wasserman, MD Ph.D, Reader in Infectious Diseases at St Georges University of London and Associate Professor in the Division of Infectious Diseases and HIV Medicine at University of Cape Town, SA. Editor of AAC.
- Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models
- GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment
- Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs
- Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis
- Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
- Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
- Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models
- Therapeutic Potential of Coumestan Pks13 Inhibitors for Tuberculosis
- In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis
This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up.
Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.